ResMed Inc.
RMD
$220.22
-$5.57-2.47%
| Weiss Ratings | RMD - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Good | |||
| Risk Index | Fair | |||
| Risk Grade | C- | |||
| Reward Grade | B | |||
| Rating Factors | RMD - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Weak | |||
| Growth Index | Excellent | |||
| Efficiency Index | Excellent | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Fair | |||
| Beta / Standard Deviation | RMD - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.18 | |||
| Price History | RMD - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -5.53% | |||
| 30-Day Total Return | -11.70% | |||
| 60-Day Total Return | -10.20% | |||
| 90-Day Total Return | -9.50% | |||
| Year to Date Total Return | -3.40% | |||
| 1-Year Total Return | 14.68% | |||
| 2-Year Total Return | 8.82% | |||
| 3-Year Total Return | -4.34% | |||
| 5-Year Total Return | 68.79% | |||
| 52-Week High % Change | -14.16% | |||
| 52-Week Low % Change | 31.13% | |||
| Price | RMD - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $263.05 | |||
| 52-Week Low Price | $172.19 | |||
| 52-Week Low Price (Date) | Apr 17, 2024 | |||
| 52-Week High Price (Date) | Jan 30, 2025 | |||
| Valuation | RMD - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 33.10B | |||
| Enterprise Value | 33.41B | |||
| Price/Earnings (TTM) | 26.66 | |||
| Earnings Per Share (TTM) | 8.47 | |||
| Earnings Per Share Growth | 40.01% | |||
| Price/Earnings To Growth | 0.67 | |||
| Price/Sales (TTM) | 6.76 | |||
| Price/Book (Q) | 6.31 | |||
| Enterprise Value/Revenue (TTM) | 6.78 | |||
| Price | $220.22 | |||
| Enterprise Value/EBITDA (TTM) | 19.51 | |||
| Enterprise Value/EBIT | 21.41 | |||
| Market Cap Category | Large Cap | |||
| Dividends and Shares | RMD - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 147.48M | |||
| Dividend Yield | 0.92% | |||
| Div. Per Share (Most Recent) | $0.53 | |||
| Dividend Per Share (TTM) | $2.07 | |||
| Payout Ratio (TTM) | 23.76% | |||
| Dividend Per Share (Most Recent) | $0.53 | |||
| Company Info | RMD - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 858-836-5000 | |||
| Address | 9001 Spectrum Center Boulevard San Diego, CA 92123 | |||
| Website | www.resmed.com | |||
| Country | United States | |||
| Year Founded | 1989 | |||
| Profitability | RMD - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 31.67% | |||
| Profit Margin | 25.34% | |||
| Management Effectiveness | RMD - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 13.89% | |||
| Return on Equity | 25.65% | |||
| Income Statement | RMD - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 4.93B | |||
| Total Revenue (TTM) | 4.93B | |||
| Revenue Per Share | $33.41 | |||
| Gross Profit (TTM) | 2.91B | |||
| EBITDA (TTM) | 1.71B | |||
| EBIT (TTM) | 1.56B | |||
| Net Income (TTM) | 1.25B | |||
| Net Income Avl. to Common (TTM) | 1.25B | |||
| Total Revenue Growth (Q YOY) | 10.26% | |||
| Earnings Growth (Q YOY) | 65.05% | |||
| EPS Diluted (TTM) | 8.47 | |||
| EPS Diluted Growth (Q YOY) | 64.89% | |||
| Balance Sheet | RMD - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 521.94M | |||
| Cash Per Share (Q) | $3.54 | |||
| Total Current Assets (Q) | 2.84B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 5.25B | |||
| Current Ratio (Q) | 3.329 | |||
| Book Value Per Share (Q) | $35.77 | |||
| Total Assets (Q) | 7.14B | |||
| Total Current Liabilities (Q) | 851.96M | |||
| Total Debt (Q) | 839.74M | |||
| Total Liabilities (Q) | 1.89B | |||
| Total Common Equity (Q) | 5.25B | |||
| Cash Flow | RMD - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -114.21M | |||
| Cash from Financing (TTM) | -1.03B | |||
| Net Change in Cash (TTM) | 311.70M | |||
| Levered Free Cash Flow (TTM) | 1.06B | |||
| Cash from Operations (TTM) | 1.48B | |||
